---
schema_version: "secwatch.filing_event.v1"
accession: "0001393905-24-000057"
form_type: "8-K"
ticker: "STME"
cik: "0001493712"
company_name: "Stimcell Energetics Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:39:05.991036+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Cell MedX director Brad Hargreaves resigns from board, no disagreement cited

## Summary
- Brad Hargreaves resigned from Cell MedX's Board of Directors effective February 27, 2024.
- Resignation not due to any disagreement with the Company's operations, policies, or practices.
- Cell MedX has not yet filled the vacancy left by Hargreaves' departure.
- Company thanked Hargreaves for his contributions and wished him success.

## SEC filing metadata
- accession: 0001393905-24-000057
- form_type: 8-K
- ticker: STME
- cik: 0001493712
- company_name: Stimcell Energetics Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1493712/000139390524000057/0001393905-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1493712/000139390524000057/cmxc-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001393905-24-000057
- JSON: https://secwatch.observer/filing/0001393905-24-000057.json
- Plain text: https://secwatch.observer/filing/0001393905-24-000057.txt

## Key facts
- Executive change
  Brad Hargreaves resigned as Director at Stimcell Energetics Inc..
  - Action: resigned
  - Role: Director
  source text: On February 27, 2024, Mr. Brad Hargreaves resigned from the Board of Directors of Cell MedX Corp. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1493712/000139390524000057/0001393905-24-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.